Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Gain Therapeutics's enterprise value was $35.37M on Nov 11, 2026, against $117.50M a year earlier. Over the last 5 years it ranged from $1.69M to $117.50M, with a median of $36.70M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $35.37M | -67.1% |
| 2025 | Dec 31, 2025 | $107.42M | +141.5% |
| 2024 | Dec 31, 2024 | $44.49M | +48.4% |
| 2023 | Dec 29, 2023 | $29.98M | +99.6% |
| 2022 | Dec 30, 2022 | $15.02M | -37.9% |
| 2021 | Dec 31, 2021 | $24.20M | – |
See a number that looks wrong?